Centiva Capital LP Sells 5,817 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Centiva Capital LP reduced its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 25.9% in the 4th quarter, HoldingsChannel reports. The firm owned 16,673 shares of the company’s stock after selling 5,817 shares during the quarter. Centiva Capital LP’s holdings in Harmony Biosciences were worth $574,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in HRMY. Vanguard Group Inc. grew its stake in shares of Harmony Biosciences by 36.4% in the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company’s stock valued at $162,883,000 after buying an additional 1,262,362 shares during the period. Marshall Wace LLP grew its stake in Harmony Biosciences by 165.2% in the fourth quarter. Marshall Wace LLP now owns 929,744 shares of the company’s stock valued at $31,992,000 after acquiring an additional 579,103 shares during the period. Norges Bank bought a new stake in shares of Harmony Biosciences during the fourth quarter valued at approximately $16,118,000. Pacer Advisors Inc. raised its position in shares of Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after purchasing an additional 351,582 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Harmony Biosciences by 173.9% in the 4th quarter. Invesco Ltd. now owns 449,180 shares of the company’s stock worth $15,456,000 after purchasing an additional 285,156 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock opened at $34.05 on Friday. The firm has a market capitalization of $1.96 billion, a P/E ratio of 16.14, a price-to-earnings-growth ratio of 0.47 and a beta of 0.82. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The business’s fifty day simple moving average is $31.38 and its 200 day simple moving average is $34.01. Harmony Biosciences Holdings, Inc. has a 12 month low of $26.47 and a 12 month high of $41.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $184.73 million for the quarter, compared to the consensus estimate of $184.26 million. During the same period in the previous year, the firm earned $0.67 EPS. The firm’s quarterly revenue was up 19.5% on a year-over-year basis. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

HRMY has been the subject of a number of recent research reports. Needham & Company LLC restated a “buy” rating and set a $49.00 price target on shares of Harmony Biosciences in a research note on Tuesday. Deutsche Bank Aktiengesellschaft began coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Harmony Biosciences in a report on Tuesday, April 8th. UBS Group dropped their target price on Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating on the stock in a report on Monday, April 28th. Finally, Mizuho upped their price target on Harmony Biosciences from $42.00 to $44.00 and gave the stock an “outperform” rating in a report on Tuesday, March 18th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $52.33.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.